Claims for Patent: 7,423,050

Summary for Patent: 7,423,050

Title:	Pyridinoylpiperidines as 5-HT.sub.1F agonists
Abstract:	The present invention relates to compounds of formula I: ##STR00001## or pharmaceutically acceptable acid addition salts thereof, where; R.sup.1 is C.sub.1-C.sub.6 alkyl, substituted C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, substituted C.sub.3-C.sub.7 cycloalkyl, C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, substituted C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R.sup.2 is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.6 cycloalkyl-C.sub.1-C.sub.3 alkyl, or a group of formula II ##STR00002## R.sup.3 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.4 is hydrogen, halo, or C.sub.1-C.sub.3 alkyl; R.sup.5 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.6 is hydrogen or C.sub.1-C.sub.6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT.sub.1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
Inventor(s):	Cohen; Michael Philip (Indianapolis, IN), Kohlman; Daniel Timothy (Camby, IN), Liang; Sidney Xi (Bethany, CT), Mancuso; Vincent (Thy-le-Chateau, BE), Xu; Yao-Chang (Fishers, IN), Ying; Bai-Ping (Fishers, IN), Zacherl; DeAnna Piatt (Noblesville, IN), Zhang; Deyi (Carmel, IN), Victor; Frantz (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	10/509,770
Patent Claims:	1. A compound of formula I: ##STR00102## or a pharmaceutically acceptable acid addition salt thereof, where; R.sup.1 is phenyl substituted with one to three halo substituents; R.sup.2 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.3 is hydrogen or methyl; R.sup.4 is hydrogen; and R.sup.5 is hydrogen. 2. The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benz- amide or a pharmaceutically acceptable acid addition salt thereof. 3. The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benz- amide hemisuccinate salt. 4. The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benz- amide hydrochloride salt. 5. A pharmaceutical formulation comprising an effective amount of a compound of claim 1 and a pharmaceutical carrier, diluent, or excipient. 6. A pharmaceutical formulation comprising an effective amount of a compound of claim 2 and a pharmaceutical carrier, diluent, or excipient. 7. A pharmaceutical formulation comprising an effective amount of a compound of claim 3 and a pharmaceutical carrier, diluent, or excipient. 8. A pharmaceutical formulation comprising an effective amount of a compound of claim 4 and a pharmaceutical carrier, diluent, or excipient. 9. A method for the treatment of migraine in a mammal in need thereof comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I: ##STR00103## or a pharmaceutically acceptable acid addition salt thereof, where; R.sup.1 is phenyl, substituted with one to three halo substituents; R.sup.2 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.3 is hydrogen or methyl; R.sup.4 is hydrogen; and R.sup.5 is hydrogen. 10. The method according to claim 9 wherein the mammal is a human.